CC-486

DRUG18 trials

Conditions

AMLAcute Myelogenous Leukemia (AML)Acute Myeloid LeukemiaBreast CancerBreast NeoplasmsCMMLCarcinoma, Non-Small-Cell LungCarcinoma, Pancreatic Ductal

Phase 1

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

CompletedNCT01478685

CelgeneCarcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Carcinoma, Transitional Cell +5

Start: 2011-11-29End: 2015-11-17Updated: 2019-11-12

Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation (HSCT) in Participants With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndromes (MDS).

CompletedNCT01835587

CelgeneLeukemia, Myeloid, Acute, Myelodysplastic Syndromes

Start: 2013-10-25End: 2017-05-26Updated: 2018-11-20

Bioequivalence & Food Effect Study in Patients With Solid Tumor or Hematologic Malignancies

CompletedNCT02223052

CelgeneAcute Myeloid Leukemia, Breast Cancer, Genitourinary +17

Start: 2014-10-27End: 2018-12-18Updated: 2020-05-12

A Dose-Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Follicular Lymphoma

TerminatedNCT04722601

University of ChicagoFollicular Lymphoma

Start: 2021-09-01End: 2023-03-31Updated: 2024-05-16

A Study to Assess Safety and Tolerability of CC-486 (ONUREG®, Oral Azacitidine) in Combination Therapy in Participants With Acute Myeloid Leukemia (AML)

CompletedNCT04887857

CelgeneLeukemia, Myeloid, Acute

Start: 2021-12-01End: 2024-01-08Updated: 2024-02-12

CC-486 and Venetoclax for Acute Myeloid Leukemia

RecruitingNCT05287568

University of Colorado, DenverAML

Start: 2022-12-19End: 2029-03-31Target: 35Updated: 2026-01-15

Phase 2

Safety and Efficacy Study of Nab®-Paclitaxel With CC-486 or Nab®-Paclitaxel With Durvalumab, and Nab®-Paclitaxel Monotherapy as Second/Third-line Treatment for Advanced Non-small Cell Lung Cancer

CompletedNCT02250326

CelgeneCarcinoma, Non-Small-Cell Lung

Start: 2015-01-07End: 2023-08-17Updated: 2024-09-19

Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma

CompletedNCT02269943

CelgeneNasopharyngeal Neoplasms

Start: 2015-02-13End: 2017-04-20Updated: 2018-12-12

Study to Assess the Efficacy and Safety of the Epigenetic Modifying Effects of CC-486 (Oral Azacitidine) in Combination With Fulvestrant

TerminatedNCT02374099

CelgeneBreast Neoplasms

Start: 2015-03-13End: 2017-11-21Updated: 2018-12-14

A Study to Evaluate Long-term Safety of CC-486 (Oral Azacitidine) in Subjects With Hematological Disorders

CompletedNCT02494258

CelgeneHematologic Malignancies, Hematologic Neoplasm, Neoplasms

Start: 2015-10-22End: 2025-04-14Updated: 2026-04-02

Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer

TerminatedNCT02546986

CelgeneCarcinoma, Non-Small-Cell Lung

Start: 2015-10-09End: 2025-07-07Updated: 2026-07-22

Study of Pembrolizumab With or Without CC-486 in Patients With Platinum-resistant Ovarian Cancer

TerminatedNCT02900560

Translational Research in OncologyEpithelial Ovarian Cancer

Start: 2016-12-20End: 2021-05-27Updated: 2022-06-10

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

CompletedNCT03493646

Kirby InstituteAcute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, Myelodysplastic Syndromes

Start: 2018-05-18End: 2021-09-21Updated: 2024-05-28

A Study of Lenalidomide and CC-486 With Radiation Therapy in Patients With Plasmacytoma

Active, not recruitingNCT04174196

Memorial Sloan Kettering Cancer CenterMultiple Myeloma, Plasmacytoma, Plasmacytoma of Bone

Start: 2019-11-19End: 2026-11-19Updated: 2025-12-02

Study of Magrolimab Combinations in Participants With Myeloid Malignancies

TerminatedNCT04778410

Gilead SciencesMyeloid Malignancies

Start: 2021-06-28End: 2024-03-04Updated: 2025-03-20

Pilot Study of CC 486 (Oral Azacitidine) Plus BSC as Maintenance After sc Azacitidine in Elderly HR-IPSS-R MDS Patients

CompletedNCT04806906

University of FlorenceCMML, MDS

Start: 2021-03-24End: 2025-01-24Updated: 2026-05-06

An Efficacy and Safety Study of Oral Azacitidine (CC-486) as Maintenance Therapy in Chinese Participants With Acute Myeloid Leukemia in Complete Remission

Active, not recruitingNCT05413018

Bristol-Myers SquibbLeukemia, Myeloid, Acute

Start: 2022-08-19End: 2026-10-31Updated: 2026-04-28

Unknown Phase

Expanded Access for CC-486

NCT03723135

CelgeneAcute Myelogenous Leukemia (AML)

Updated: 2020-09-18

Blood Advances2026-07-24

Abstract CT260: Pembrolizumab and epigenetic modification with azacitidine reprogram the tumor microenvironment of platinum-resistant epithelial ovarian cancer: clinical and translational findings from a phase II study

Cancer Research2026-04-17

Pembrolizumab and epigenetic modification with azacitidine reshapes the tumor microenvironment of platinum-resistant epithelial ovarian cancer: a phase 2 non-randomized clinical trial

Communications Medicine2026-02-06

Phase 2 Multi‐Arm Study of Magrolimab Combinations in Patients With Acute Myeloid Leukaemia

eJHaem2025-05-131 citations

Clinical Response to Azacitidine in Myelodysplastic Neoplasms Is Associated with Distinct DNA Methylation Changes in Haematopoietic Stem and Progenitor Cells <i>In Vivo</i>

Blood2024-11-05

Abstract 7551: Combined epigenetic therapy and immune checkpoint blockade drive reshaping of the tumor microenvironment of platinum resistant ovarian cancer

Cancer Research2024-03-223 citations

Treatment of Elderly Patients with Higher Risk Myelodysplastic Syndromes with Oral Azacitidine

Blood2023-11-02

P567: PHASE 1B OMNIVERSE TRIAL: SAFETY AND TOLERABILITY OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF ACUTE MYELOID LEUKEMIA

HemaSphere2023-08-01

Phase 1b OMNIVERSE trial: Safety and tolerability of oral azacitidine (Oral-AZA) in combination with venetoclax (VEN) for treatment of acute myeloid leukemia.

Journal of Clinical Oncology2023-06-012 citations

Results from a phase (Ph) 1 clinical study of the all-oral regimen of CC-486 and venetoclax for acute myeloid leukemia (AML).

Journal of Clinical Oncology2023-06-011 citations

Treatment with Oral Azacitidine in Elderly Patients with Higher Risk Myelodysplastic Syndromes after Response to Subcutaneous Azacitidine

Blood2022-11-15

Oral azacitidine plus venetoclax in patients with relapsed/refractory or newly diagnosed acute myeloid leukemia: The phase 1b OMNIVERSE trial.

Journal of Clinical Oncology2022-06-01

P499: THE PHASE 1B OMNIVERSE TRIAL OF ORAL AZACITIDINE IN COMBINATION WITH VENETOCLAX FOR TREATMENT OF RELAPSED/REFRACTORY OR NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (TRIAL IN PROGRESS)

HemaSphere2022-06-01

P553: A PHASE 2, OPEN-LABEL, MULTIARM, MULTICENTER STUDY TO EVALUATE MAGROLIMAB COMBINED WITH ANTILEUKEMIA THERAPIES FOR FIRST-LINE, RELAPSED/REFRACTORY, OR MAINTENANCE TREATMENT OF ACUTE MYELOID LEUKEMIA

HemaSphere2022-06-01

Venetoclax Shows Low Therapeutic Activity in BCL2-Positive Relapsed/Refractory Peripheral T-Cell Lymphoma: A Phase 2 Study of the Fondazione Italiana Linfomi

Frontiers in Oncology2021-12-069 citations

A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia

Blood2021-11-052 citations

OMNIVERSE: A Phase 1b/2 Study of Oral Azacitidine Plus Venetoclax in Patients with Relapsed/Refractory (R/R) or Newly Diagnosed (ND) Acute Myeloid Leukemia (AML)

Blood2021-11-051 citations

A Multicenter, Single-Arm, Phase I/II Dose Finding and Efficacy Study of Venetoclax, CC-486, and Obinutuzumab in Minimally-Pretreated Follicular Lymphoma

Blood2021-11-05

nab-Paclitaxel Plus Durvalumab in Patients With Previously Treated Advanced Stage Non-small Cell Lung Cancer (ABOUND.2L+)

Frontiers in Oncology2021-02-114 citations

A Pilot Study Evaluating Lenalidomide and CC-486 in Combination with Radiotherapy for Patients with Plasmacytoma (LENAZART study)

Blood2020-11-041 citations

7 more papers not shown

CC-486

Sponsors

Conditions

Phase 1

Phase 2

Unknown Phase

Related Papers